PR Newswire
– Presentations Showcase Eiger’s Innovative Therapies for Hepatitis Delta Virus
PALO ALTO, Calif.
,
June 8, 2022
/PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced four abstracts to be presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 taking place
June 22-26
in
London, United Kingdom
.
Oral presentation:
Title:
Lonafarnib Combination with Peginterferon Lambda Diminished Triphasic HDV Kinetic Pattern
Seen Under Lambda Monotherapy: the
LIFT-1
HDV Study
Authors:
Duehren, S.; Heller, T. et al.
Session:
Hepatitis B Emerging Therapies
Date & Time:
June 25
,
8:30 a.m. – 8:45 a.m.
British Summer Time (BST)
Abstract #:
1904
Presenter:
Harel Dahari
Poster presentations:
Title:
Strong Correlation Between HBsAg, ALT and HDV-RNA Levels in Patients with Chronic Hepatitis
Delta: Results of Phase 3
D-LIVR
Study
Authors:
Buti, M.; Lampertico, P. et al.
Session:
Viral Hepatitis A, B, C, D, E: Virology
Date & Time:
June 23
, 9:00 a.m. – 6:30 p.m. BST
Abstract #:
3494
Title:
Clinical Features Predictive of Cirrhosis in a Large Cohort of Patients with Chronic Hepatitis Delta Infection – Insights from the
D-LIVR
Trial
Authors:
Etzion, O.; Lampertico, P. et al.
Session:
Viral Hepatitis B/D: Clinical Aspects Except Therapy
Date & Time:
June 23
, 9:00 a.m. – 6:30 p.m. BST
Abstract #:
3442
Title:
Mathematical Modeling of HDV RNA Kinetics Suggests High Peginterferon Lambda Efficacies in Blocking Viral Production and Infection: Insights from the
LIMT-1
Study
Authors:
Cardozo-Ojeda,
,
E.F.; Etzion, O. et al
Session:
Viral Hepatitis B/D: Therapy
Date & Time:
June 25
,
9:00 a.m. – 6:00 p.m. BST
Abstract #:
2072
Additional Congress Activities:
Event:
21
st
Hepatitis Delta International Network
Presentation Title:
Lonafarnib and Peginterferon Lambda: Monotherapy and Combination Treatments in Late-Stage Development for HDV
Date & Time:
June 22
, 4:00 p.m. BST
Location:
ExCel
London
, South Gallery 27
Presenter:
Ingrid Choong, Ph.D., SVP, Clinical Development Eiger BioPharmaceuticals
Event:
Eiger Booth #101
Date & Time:
June 23-25
, 9:00 a.m. – 5:00 p.m. BST
Event:
Eiger Reception for Investigators, Investors and Analysts
Date:
June 23
, 5:30 – 7:00 p.m. BST
Location:
Prince Regent #3
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Eiger is also developing peginterferon lambda as a therapeutic for COVID-19 and reported positive results from
TOGETHER,
a Phase 3 investigator-initiated study.
All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia.
For additional information about Eiger and its clinical programs, please visit
www.eigerbio.com
.
Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
[email protected]
Media:
Sarah Mathieson
SVP, Corporate Affairs
[email protected]
View original content to download multimedia:
https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-multiple-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022-301563811.html
SOURCE Eiger BioPharmaceuticals, Inc.
